Ola Fjellström

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 7

Top Topics

St Segment Elevation Myocardial Infarction

Acute Coronary Syndrome

Placebo Controlled

Top Venues

Journal of the American Heart Association

Hepatology communications

This page only lists publications with an associated author ORCID identifier.

Publications

Dimitris Kardassis, Ann-Charlotte Egnell, Magnus Åstrand, Samuel J Daniels, Carl Whatling, Ola Fjellström, Anders Gabrielsen
Safety, Tolerability, and Pharmacodynamics of AZD3366 (Optimized Human CD39L3 Apyrase) Alone and in Combination With Ticagrelor and Acetylsalicylic Acid: A Phase 1, Randomized, Placebo-Controlled Study. Journal of the American Heart Association 13 (11) (2024)
Dimitris Kardassis, Ann-Charlotte Egnell, Magnus Åstrand, Samuel J Daniels, Carl Whatling, Ola Fjellström, Anders Gabrielsen
Safety, Tolerability, and Pharmacodynamics of AZD3366 (Optimized Human CD39L3 Apyrase) Alone and in Combination With Ticagrelor and Acetylsalicylic Acid: A Phase 1, Randomized, Placebo-Controlled Study. Journal of the American Heart Association 13 (11) (2024)
Dimitris Kardassis, Ann-Charlotte Egnell, Magnus Åstrand, Samuel J Daniels, Carl Whatling, Ola Fjellström, Anders Gabrielsen
Safety, Tolerability, and Pharmacodynamics of AZD3366 (Optimized Human CD39L3 Apyrase) Alone and in Combination With Ticagrelor and Acetylsalicylic Acid: A Phase 1, Randomized, Placebo-Controlled Study. Journal of the American Heart Association 13 (11) (2024)
Dimitris Kardassis, Ann-Charlotte Egnell, Magnus Åstrand, Samuel J Daniels, Carl Whatling, Ola Fjellström, Anders Gabrielsen
Safety, Tolerability, and Pharmacodynamics of AZD3366 (Optimized Human CD39L3 Apyrase) Alone and in Combination With Ticagrelor and Acetylsalicylic Acid: A Phase 1, Randomized, Placebo-Controlled Study. Journal of the American Heart Association (2024)
Dimitris Kardassis, Ann-Charlotte Egnell, Magnus Åstrand, Samuel J Daniels, Carl Whatling, Ola Fjellström, Anders Gabrielsen
Safety, Tolerability, and Pharmacodynamics of AZD3366 (Optimized Human CD39L3 Apyrase) Alone and in Combination With Ticagrelor and Acetylsalicylic Acid: A Phase 1, Randomized, Placebo-Controlled Study. Journal of the American Heart Association 13 (11) (2024)
Dimitris Kardassis, Ann-Charlotte Egnell, Magnus Åstrand, Samuel J Daniels, Carl Whatling, Ola Fjellström, Anders Gabrielsen
Safety, Tolerability, and Pharmacodynamics of AZD3366 (Optimized Human CD39L3 Apyrase) Alone and in Combination With Ticagrelor and Acetylsalicylic Acid: A Phase 1, Randomized, Placebo-Controlled Study. Journal of the American Heart Association 13 (11) (2024)
Elke Ericson, Linnéa Bergenholm, Anne-Christine Andréasson, Carly I Dix, Jane Knöchel, Sara F Hansson, Richard G Lee, Jennifer Schumi, Madeleine Antonsson, Ola Fjellström, Patrik Nasr, Mathias Liljeblad, Björn C L Carlsson, Stergios Kechagias, Daniel Lindén, Mattias Ekstedt
Hepatic patatin-like phospholipase domain-containing 3 levels are increased in I148M risk allele carriers and correlate with NAFLD in humans. Hepatology communications 6 (10) (2022)